產(chǎn)品詳情
簡單介紹：
Anti-SPOPL抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-SPOPL抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-SPOPL
Cat. Number:
Anti-SPOPL抗體KL-17684R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
SPOPL is a 392 amino acid nuclear protein that may be involved in ubiquitination and proteasomal degradation processes. Belonging to the Tdpoz family, SPOPL contains one BTB (POZ) domain and one MATH domain. Anti-SPOPL抗體SPOPL forms a complex with a member of the cullin family. The gene that encodes SPOPL includes 71,768 bases, four transcripts and maps to the human chromosome 2q22.1. Chromosomal arm 2q22-23 has been identified as one of fifteen hot spots thought to be involved in head and neck squamous cell carcinoma (HNSCC). Chromosome 2, which consists of 237 million bases, encodes over 1,400 genes and makes up approximately 8% of the human genome. A number of genetic diseases are linked to genes on chromosome 2 including Harlequin icthyosis, sitosterolemia and Alstr鰉 syndrome.
Also known as:
HIB homolog 2; SPOPL_HUMAN; Anti-SPOPL抗體Roadkill homolog 2; Speckle type POZ protein like.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Chicken, Pig, Cow, Horse, Rabbit, .
●
Immunogen: KLH conjugated synthetic peptide derived from human SPOPL.
●
Predicted Molecular Weight:Anti-SPOPL抗體 45kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-SPOPL抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
